Eric A. Finkelstein
National University of Singapore
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eric A. Finkelstein.
Health Affairs | 2009
Eric A. Finkelstein; Justin G. Trogdon; Joel W. Cohen; William Dietz
In 1998 the medical costs of obesity were estimated to be as high as
Circulation | 2011
Paul A. Heidenreich; Justin G. Trogdon; Olga Khavjou; Javed Butler; Kathleen Dracup; Michael D. Ezekowitz; Eric A. Finkelstein; Yuling Hong; S. Claiborne Johnston; Amit Khera; Donald M. Lloyd-Jones; Sue A. Nelson; Graham Nichol; Diane Orenstein; Peter W.F. Wilson; Y. Joseph Woo
78.5 billion, with roughly half financed by Medicare and Medicaid. This analysis presents updated estimates of the costs of obesity for the United States across payers (Medicare, Medicaid, and private insurers), in separate categories for inpatient, non-inpatient, and prescription drug spending. We found that the increased prevalence of obesity is responsible for almost
Injury Prevention | 2006
Judy A. Stevens; Phaedra S. Corso; Eric A. Finkelstein; Ted R. Miller
40 billion of increased medical spending through 2006, including
American Journal of Preventive Medicine | 2012
Eric A. Finkelstein; Olga Khavjou; Hope Thompson; Justin G. Trogdon; Liping Pan; Bettylou Sherry; William H. Dietz
7 billion in Medicare prescription drug costs. We estimate that the medical costs of obesity could have risen to
Injury Prevention | 2006
Phaedra S. Corso; Eric A. Finkelstein; Tyler Miller; I. Fiebelkorn; Eduard Zaloshnja
147 billion per year by 2008.
The Lancet | 2016
Ding Ding; Kenny D Lawson; Tracy Kolbe-Alexander; Eric A. Finkelstein; Peter T. Katzmarzyk; Willem van Mechelen; Michael Pratt
Background— Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. Methods and Results— To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008
Journal of Occupational and Environmental Medicine | 2010
Eric A. Finkelstein; Marco DiBonaventura; Somali M. Burgess; Brent C. Hale
) total direct medical costs of CVD are projected to triple, from
American Journal of Health Promotion | 2005
Eric A. Finkelstein; Ian C. Fiebelkorn; Guijing Wang
273 billion to
Obesity Reviews | 2008
Justin G. Trogdon; Eric A. Finkelstein; T. Hylands; Pam S. Dellea; Sachin Kamal-Bahl
818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from
American Journal of Preventive Medicine | 2011
Eric A. Finkelstein; Kiersten L. Strombotne; Nadine L. Chan; James Krieger
172 billion in 2010 to